In addition, racially disparate expression of MYB in Black and White prostate cancer warrants future studies to characterize mechanisms underlying its dysregulation in these racial subgroups and investigate if MYB targeting could be helpful in closing the disparity gaps. This evidence concerns the gene MYB and prostate carcinoma.